Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence-Reference-Cited by-同舟云学术

Immunogenicity and safety of the 13-valent pneumococcal conjugate vaccine in patients with immunocompromising conditions: a review of available evidence

Published:2020-06-12 Issue:11 Volume:16 Page:2758-2772
ISSN:2164-5515
Container-title:Human Vaccines & Immunotherapeutics
language:en
Short-container-title:Human Vaccines & Immunotherapeutics

Author:

Chilson Erica¹,Scott Daniel A.²^ORCID,Schmoele-Thoma Beate³^ORCID,Watson Wendy²,Moran Mary M.¹,Isturiz Raul¹

Affiliation:

1. Vaccine Medical Development & Scientific/Clinical Affairs, Pfizer Inc, Collegeville, PA, USA

2. Vaccine Clinical Research and Development, Pfizer Inc, Collegeville, PA, USA

3. Vaccine Clinical Research and Development, Pfizer Pharma GmbH, Berlin, Germany

Funder

Pfizer

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/21645515.2020.1735224

Reference62 articles.

1. Streptococcus pneumoniae colonisation: the key to pneumococcal disease

2. Risk of underlying chronic medical conditions for invasive pneumococcal disease in adults

3. Risk of Pneumococcal Disease in Children With Chronic Medical Conditions in the Era of Pneumococcal Conjugate Vaccine

4. Rates of Pneumococcal Disease in Adults With Chronic Medical Conditions

5. Invasive Pneumococcal Disease Among Immunocompromised Persons: Implications for Vaccination Programs

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of Adverse Events Post-13-Valent Pneumococcal Vaccination among Children in Hangzhou, China;Vaccines;2024-05-25

2. Dutch Healthcare Professionals’ Opinion on the Allocation of Responsibilities concerning Prescribing and Administering Medically Indicated Vaccines to Immunocompromised Patients;Vaccines;2023-03-17

3. Surveillance of adverse events following immunization of 13-valent pneumococcal conjugate vaccine among infants, in Zhejiang province, China;Human Vaccines & Immunotherapeutics;2022-01-31

4. Reducing Delays in Diagnosing Primary Immunodeficiency Through the Development and Implementation of a Clinical Decision Support Tool: Protocol for a Quality Improvement Project;JMIR Research Protocols;2022-01-04

5. Pivotal Phase 3 Randomized Clinical Trial of the Safety, Tolerability, and Immunogenicity of 20-Valent Pneumococcal Conjugate Vaccine in Adults Aged ≥18 Years;Clinical Infectious Diseases;2021-12-23